基于"分子兼容性理论"和临床应用的Elemene抗瘤药物开发:回顾和前性展望
Xiao-Ying Jiang1,2,3,4, Li-Ping Shi5, Jun-Long Zhu1,2,3,4
1School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
Chinese journal of integrative medicine
|October 26, 2023
概括
埃莱是Curcuma wenyujin中的一种化合物,显示出显著的抗瘤作用. 它的发展以分子兼容性理论为指导,导致了用于增强癌症治疗的先进纳米脂质体配方.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 传统中国医药 传统中国医药
背景情况:
- 来自Curcuma wenyujin的Elemene具有公认的抗瘤特性.
- 临床应用突出了它对各种瘤的有效性.
- 这是一个很棒的节目,这是一个很棒的节目.
- 部长 部长 部长 部长
- , , , 这是一个很好的方法.
- 助理 助理 助理 助理
- , 和, 和, 和, 和.
- 发言人 代表 代表 代表 代表 代表
- 来自中国医学的理论是一个基本的概念.
研究的目的:
- 审查抗瘤机制和elemene的临床应用.
- 探索基于元素的药物输送系统和结构修改方面的进展.
- 建立一个理论框架,使用分子兼容性理论开发新型抗瘤药物.
主要方法:
- 对中国医学原则和现代生物医学知识的系统分析.
- 开发元素纳米脂质体配方.
- 对Elementene的抗瘤活性,临床研究和药物输送系统的当前研究进行了审查.
主要成果:
- 元素纳米脂质体表现出低毒性,定义的组成,协同的多目标效应和良好的生物相容性.
- 分子兼容性理论为优化元素的治疗潜力提供了一个框架.
- 目前的研究表明,基于元素的癌症疗法有前途.
结论:
- 作为一种抗瘤剂,Elemene具有显著的前景.
- 分子兼容性理论为癌症药物开发提供了一种新的方法.
- 进一步的研究是有必要的,以充分利用元素在瘤学的潜力.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


